drugset
drugset / Trial / NCT00464789

Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Healthy Postmenopausal Women

NCT00464789 ↗

Phase 1 Completed Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedCrossoverOpen-labelTreatment

Summary

Bazedoxifene/Conjugated Estrogens (BZA/CE) is an investigational drug that is being developed for treatment of menopause. The purpose of this trial is to compare a new manufacturing process for making BZA/CE to the current process by assessing the way it is absorbed into the blood.

Timeline

Start
2007-03
Primary completion
—
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Bazedoxifene Other / unclassified 20 mg —
Subject conjugated estrogens Other / unclassified 0.625 mg —

Indications

No indication recorded.